QuantuMDx - Changing healthcare, Globally

QuantuMDx Group Logo
Tackling humanitarian
health priorities
Malaria, TB & HIV diagnosis and drug resistance status for a few dollars
The Handheld Laboratory
15 minute disease diagnosis at the
touch of a button
Personalising Medicine
Right first time prescribing for your patients
Digitizing Biology
Translating DNA the code of life into binary code
One Device,
Endless Possibilities
Flexibility to extract and analyse DNA from most sample types
Our Commercial testing laboratory
One Device, Endless Possibilities™
Q-POC™: The Handheld Laboratory

Q-POC™: The Handheld Laboratory.
QuantuMDx is The Future. Our handheld laboratory will deliver complex diagnostics in minutes for a few dollars in any setting across the globe.

QuantuMDx is The Future

Our handheld laboratory will deliver complex diagnostics in
minutes for a few dollars in any setting across the globe.


Making disease eradication a reality

Q-POC™ our handheld laboratory, will provide health workers with the definitive tool
to diagnose, manage, monitor and track emerging infections and drug resistance.


  • Results in 10-15 minutes
  • Disease diagnosis & drug resistance testing
  • Directs right first time prescribing
  • Handheld, user friendly, low cost
  • Single button operation
  • Mobile data connection

Our Devices

QuantuMDx invited to Wellcome Trust’s Review of Antimicrobial Resistance

Jonathan O’Halloran has been invited to sit on a diagnostics panel at the Wellcome Trust’s first event of the Review of Antimicrobial Resistance, an event tackling a crisis for the health and wealth of nations.

Double honours as CSO named ‘Pioneer’ and CEO one of ’50 Movers & Shakers in BioBusiness 2014’

CEO Elaine Warburton was named a BioBusiness Mover & Shaker by BioBeat in a report on women challenging the status quo in Britain, while CSO Jonathan O’Halloran was titled ‘Pioneer’ by Connected World for his Internet of Life vision.
Read more >

QuantuMDx exhibiting at MEDICA 2014

The company will be exhibiting, with a stand at E22 in Hall 1, and non-working demo Q-POC devices on hand. On Thursday at 4pm a stand party will be held sharing “A Taste of North East England”, with Newcastle Brown Ale and Durham Gin available.
Read more >

FIND and QuantuMDx partnering to developing breakthrough technology for tuberculosis detection and drug resistance determination

FIND, a Geneva-based non-profit organization and QuantuMDx Group, a British medical device developer are joining forces in developing a paradigm changing solution for the combined detection of and drug susceptibility determination for the causative agent for tuberculosis. Based on the molecular detection of an extensive set of genetic markers by the simple handheld Q-POC™ device developed by QuantuMDx, the time for full antimycobacterial resistance profiling will be reduced from weeklong to less than half an hour.
Read more >

QuantuMDx announce prototype handheld lab for 15 minute DNA-based diagnosis

At the TEDMED 2014 conference, medical device developers QuantuMDx Group announced the successful production of their first fully-integrated sample-to-result working prototype of Q-POC™, a handheld lab that delivers your DNA-based medical diagnosis in minutes. The Group believes the future of disease management and drug resistance monitoring is networked geo-stamped data, a functionality provided by the handheld Q-POC™ device. Rapid and low cost testing will enable continuous monitoring of disease and antimicrobial resistance throughout populations, as well as surveillance for emerging novel pathogen threats such as Ebola.
Read more >

DNA testing company NorthGene is added to the Ministry of Justice accredited list

NorthGene Limited, one of the UK's first commercial DNA testing companies has received notification from the Ministry of Justice that their laboratory is now accredited to carry out scientific tests for parentage where the court gives a 'Section 20 direction'. NorthGene recently achieved UKAS accreditation for ISO 17025 allowing them to perform legal DNA tests. The company's testing laboratory is based within the world renown genomics hub at The International Centre for Life, Newcastle, UK where the company currently undertakes legal relationship testing for many coroners, family law solicitors, local councils and the general public alongside other legal testing including drug and alcohol testing. This new accreditation recognises NorthGene's exceptional standards of quality and laboratory & customer services and allows NorthGene to not only perform paternity, maternity and siblingship tests for legal reasons such as changes in birth certificates, inheritance cases and identification of unknown bodies for coroners but also Ministry of Justice court directed cases and parentage tests for immigration applications. This accreditation will enable the company to further expand their in-house testing portfolio and embrace additional Forensic DNA testing services for the legal system.
Read more >

CEO Elaine Warburton receives an OBE for services to health innovation

QMDx are delighted to announce our CEO Elaine Warburton receives an OBE for services to health innovation!

QuantuMDx awarded £1m grant to develop rapid multi-drug resistant TB test for their smartphone-like device

British biotech QuantuMDx has been awarded a UK government's Technology Strategy Board (TSB) grant to develop Q-TB™, a rapid and cheap test that will analyse sputum samples at the patient's side and diagnose multi-drug resistant TB (MDR-TB) within 15 minutes enabling immediate personalised prescription of the most effective TB drug treatment. TB causes 2m deaths every year despite most cases being curable. The disposable Q-TB™ cartridge will be used on Q-POC™, QuantuMDx's universal handheld diagnostic device and provide a technology leap for both developing nations which lack healthcare infrastructure and the overburdened healthcare systems of developed nations which are seeing an re-emergence of MDR-TB, particularly within inner cities. The three year £2m project will integrate QuantuMDx's state of the art DNA analysis device with a novel sputum disruption technology and a comprehensive TB biomarker panel developed by St George's, University of London and its partners. The project is particularly strong as it also embraces the expertise of various global academic TB Groups and several TB focused charities and NGOs who are currently working in the field to help eradicate the disease and who understand, first hand, what is needed for a rapid TB diagnostic.
Read more >

QuantuMDx DevicesQuantuMDx investment opportunitiesQuantuMDx MissionQuanutMDx bio technololgyQuantuMDx developing new assays